Entrada Therapeutics, Inc.
Clinical trials sponsored by Entrada Therapeutics, Inc., explained in plain language.
-
New drug aims to slow muscle decline in duchenne muscular dystrophy
Disease control Recruiting nowThis study is testing an investigational drug called ENTR-601-45 for people with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The goal is to find a safe and effective dose that may help produce a needed muscle protein and potentially slow disease progre…
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Apr 04, 2026 05:21 UTC
-
New hope for boys with devastating muscle disease
Disease control Recruiting nowThis study is testing a new drug called ENTR-601-44 for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease. It aims to see if the drug is safe, find the right dose, and check if it helps produce a needed muscle protein. The trial is for boys and young men …
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC